SuperworthRoivant Sciences revenue ROIV
Sales by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- $7.5M
- Latest quarter, Q1 FY26
- $1.4M
- −34% on a year earlier
- Fiscal year 2025
- $8.3M
- −72% on the year before
Roivant Sciences' revenue was $7.5M over the twelve months to Jun 30, 2026, down 68% on a year earlier.
In its latest quarter, Q1 FY26, it was $1.4M, down 34% on the same quarter a year before.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $8.3M | −72% |
| FY2024 | $29.1M | −58% |
| FY2023 | $69.8M | +14% |
| FY2022 | $61.3M | +11% |
| FY2021 | $55.3M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY26 | $1.4M | −34% | $7.5M | |
| Q4 FY25 | $2.5M | −67% | $8.3M | |
| Q3 FY25 | $2M | −78% | $13.3M | |
| Q2 FY25 | $1.6M | −65% | $20.3M | |
| Q1 FY25 | $2.2M | −73% | $23.2M | |
| Q4 FY24 | $7.6M | −74% | $29.1M | |
| Q3 FY24 | $9M | −42% | $50.4M | |
| Q2 FY24 | $4.5M | +23% | $57M | |
| Q1 FY24 | $8M | −63% | $56.1M | |
| Q4 FY23 | $28.9M | +6% | $69.8M | |
| Q3 FY23 | $15.6M | −9% | $68.2M | |
| Q2 FY23 | $3.6M | −71% | $69.7M |
Against its peers
Companies in Biotechnology nearest Roivant Sciences' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| ROIVRoivant Sciences | $7.5M | −68% a year |
| UTHRUnited Therapeutics | $3.2B | +2% a year |
| INCYIncyte | $5.8B | +27% a year |
| ALNYAlnylam Pharmaceuticals | $4.8B | +95% a year |
| ONCBeOne Medicines | $6.1B | +34% a year |
| EXELExelixis | $2.4B | +9% a year |
| NBIXNeurocrine Biosciences | $3.4B | +34% a year |
| HALOHalozyme Therapeutics | $1.7B | +41% a year |
| TECHBIO-TECHNE | $1.2B | −0% a year |
| RGENRepligen | $785.1M | +16% a year |
| KRYSKrystal Biotech | $440.5M | +23% a year |
| Peer median | $2.8B |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Roivant Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.